Co-Authors
This is a "connection" page, showing publications co-authored by KANWAL PRATAP SINGH RAGHAV and SHUBHAM PANT.
Connection Strength
0.714
-
Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol. 2021 Oct; 12(5):2268-2274.
Score: 0.201
-
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
Score: 0.179
-
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022 12; 23(12):1558-1570.
Score: 0.054
-
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res. 2022 06 01; 28(11):2229-2236.
Score: 0.053
-
Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
Score: 0.049
-
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415.
Score: 0.046
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.045
-
Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3.
Score: 0.044
-
Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019; 3.
Score: 0.043